Stopping the Accelerated Aging Pedal: Gene Editing and Precision Cardiovascular Medicine for HGPS
##1: The Primary Culprit of Accelerated Aging – Progerin and Nuclear Architecture Collapse Hutchinson‑Gilford Progeria Syndrome (HGPS) originates from a mutation in the LMNA gene that generates an abnormal protein called “progerin.” This toxic protein physically deforms the nuclear architecture and disables DNA‑repair mechanisms, precipitating rapid systemic aging. Historically, HGPS has been an exceptionally intractable disease; its diagnosis is highly challenging and no curative therapy existed, leaving patients and families in profound despair.
##2: Gene‑ and RNA‑Targeted Strategies for Curative Therapy Recent advances in genetics provide innovative tools to block progerin production at its source. CRISPR‑based gene‑editing directly corrects the mutant allele, while antisense oligonucleotides (ASO) intercept the translation of progerin mRNA. In addition, ICMT inhibitors and targeted modulation of the angiogenic factor Angiopoietin‑2 further contribute to precise molecular therapies that decelerate the cellular aging clock.
##3: Practical Instruments for Extending Life – Lonafarnib and High‑Risk Cardiovascular Interventions The most tangible clinical benefit to date comes from the FDA‑approved farnesyltransferase inhibitor Lonafarnib, which reduces intracellular progerin accumulation and meaningfully prolongs life expectancy. However, drug therapy alone cannot prevent fatal aortic complications; consequently, high‑complexity cardiovascular procedures such as transcatheter aortic valve replacement (TAVR) are being increasingly employed. This multidisciplinary medical‑surgical collaboration serves as a vital lifeline by lowering the risk of sudden death.
##4: Multimodal Approach to Overcoming Systemic Aging and Future Challenges The convergence of multiple therapeutic modalities is gradually making the goal of normalizing lifespan for HGPS patients realistic. Ensuring the precision and long‑term safety of gene correction will be the central challenge over the next decade. If this integrated strategy becomes established, HGPS will be redefined from an untreatable disease to a “manageable genetic condition,” offering valuable insights for the treatment of conventional age‑related disorders beyond progeria.
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder caused by a de novo point mutation in the LMNA gene, resulting in progerin, an abnormal form of lamin A. Progerin disrupts the nuclear architecture, impairs DNA repair, and alters gene expression, collectively leading to systemic premature aging. Diagnosis involves a clinical evaluation, along with genetic and radiological tests, for skeletal and cardiovascular abnormalities. To provide an overview of current and emerging therapeutic strategies for HGPS, with a focus on pharmacological, genetic, and interventional approaches aimed at mitigating disease progression and improving survival outcomes. Current treatment focuses on symptom relief and extending lifespan. Emerging therapies include gene editing, antisense oligonucleotides, ICMT inhibitors, and high-risk cardiovascular interventions. Recent studies highlight angiopoietin-2 as a potential target. Symptomatic management remains the mainstay of care, with lonafarnib, an FDA-approved farnesyltransferase inhibitor, demonstrating modest benefits in reducing progerin accumulation and improving survival. Novel approaches under investigation include gene editing techniques, antisense oligonucleotides, and inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT). Cardiovascular interventions such as transcatheter aortic valve replacement and ascending aortic constriction are being explored for high-risk patients. Recent studies also identify angiopoietin-2 modulation as a potential therapeutic avenue for vascular and skeletal repair. While lonafarnib provides modest clinical benefit, long-term management of HGPS will likely depend on advances in gene editing, RNA-based therapies, and targeted pharmacological strategies to reduce progerin toxicity. Further research is needed to enhance precision and safety in gene therapies and to explore new molecular targets for broader therapeutic impact.
If HGPS is not directly addressed for the rapid aging of children and the high risk of cardiovascular death, it leaves profound suffering for families and society. Widespread adoption of novel gene editing and cardiovascular interventions would enable patients to live longer and healthier lives.